A practical assessment protocol for clinically relevant P-glycoprotein-mediated drug-drug interactions
This protocol describes a standardized, evidence- and expert opinion-based assessment of P-gp-mediated DDIs that affect clinical outcomes. This approach will generate alerts with practice recommendations for clinically relevant DDIs and transparent rationales for DDIs that are considered to be irrelevant. These recommendations will improve individual patient care by supporting healthcare professionals to make consistent decisions on how to manage P-gp mediated DDIs.
Authors
- Lisanne M. Geers (ORCID: https://orcid.org/0000-0002-4856-2905)
- Margje H. Monster‐Simons
- Esther Brandon
- Frank G. A. Jansman (ORCID: https://orcid.org/0000-0003-2788-9578)
- Sander D. Borgsteede (ORCID: https://orcid.org/0000-0002-8425-6139)
- David S. Y. Ong (ORCID: https://orcid.org/0000-0001-5688-6443)
- Kayan Tsoi
- Leonie Bogaard (ORCID: https://orcid.org/0000-0003-1277-636X)
- Margreet van Herwaarden
- Bas van de Steeg
- Dominique Maas
Institutions
- Radboud University Nijmegen (NL)
- University of Groningen (NL)
- Utrecht University (NL)
- Radboud University Medical Center (NL)
- University Medical Center Utrecht (NL)
- Parnassia Groep (NL)
- Sint Franciscus Gasthuis (NL)
- Canisius-Wilhelmina Ziekenhuis (NL)
- Decision Sciences (United States) (US)
- Medicines Evaluation Board (NL)
- Franciscus Vlietland (NL)
- Rijnstate Hospital (NL)
- Deventer Ziekenhuis (NL)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-09-30
- DOI
- https://doi.org/10.3389/fphar.2024.1412692
- Citations
- 4
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 4.44